Drug intelligence / Profile preview

RSV LID cp ΔM2-2 vaccine

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

RSV LID cp ΔM2-2 vaccine is a live-attenuated respiratory syncytial virus (RSV) vaccine candidate designed with specific genetic modifications. It features deletion of the RSV RNA regulatory protein M2-2 (ΔM2-2) combined with cold-passage (cp) mutations. The M2-2 deletion enhances immunogenicity by inhibiting viral RNA replication while promoting F and G protein expression on the RSV surface. This vaccine is administered intranasally as a single dose.

Other names: Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID cp ΔM2-2

Beyond the preview

Go deeper on RSV LID cp ΔM2-2 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RSV LID cp ΔM2-2 vaccine.

Explore the full profile